Unknown PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT04452565

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection (NATADEX)

Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection

Sponsor: Biomed Industries, Inc.

Conditions Coronavirus Infection Severe Acute Respiratory Infection Severe Acute Respiratory Syndrome Coronavirus 2

Interventions Atazanavir and Dexamethasone Drug: NA-831 NA-831 and Atazanavir NA-831and Dexamethasone

Updated 9 times since 2020 Last updated: Jan 31, 2022 Started: Jun 15, 2022 Primary completion: Dec 15, 2023 Completion: Dec 15, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Coronavirus Infection and Severe Acute Respiratory Infection, this trial is ongoing. The trial is conducted by Biomed Industries, Inc. and has accumulated 9 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Mar 2022 — Feb 2024 [monthly]

Recruiting PHASE2_PHASE3

▶ Show 4 earlier versions

Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE2_PHASE3
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE2_PHASE3
Aug 2020 — Oct 2020 [monthly]

Recruiting PHASE2_PHASE3
Jul 2020 — Aug 2020 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biomed Industries, Inc.

Data source: Biomed Industries, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Baltimore, United States , Bethesda, United States , Boston, United States , Chicago, United States , Detroit, United States , Durham, United States , Fort Lauderdale, United States , Fort Sam Houston, United States , Galveston, United States and 20 more locations